These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 27145391)

  • 41. Effective treatment of narcolepsy-cataplexy with duloxetine: a report of three cases.
    Izzi F; Placidi F; Marciani MG; Zannino S; Torelli F; Corte F; Pisani LR; Romigi A
    Sleep Med; 2009 Jan; 10(1):153-4. PubMed ID: 18226953
    [No Abstract]   [Full Text] [Related]  

  • 42. The use of duloxetine for stress incontinence after prostatectomy.
    Hotston MR; Hurley K; Patel S; Persad R
    BJU Int; 2006 Oct; 98(4):916-7. PubMed ID: 16978296
    [No Abstract]   [Full Text] [Related]  

  • 43. Duloxetine in the treatment of social anxiety disorder.
    Crippa JA; Filho AS; Freitas MC; Zuardi AW
    J Clin Psychopharmacol; 2007 Jun; 27(3):310. PubMed ID: 17502786
    [No Abstract]   [Full Text] [Related]  

  • 44. High-dose duloxetine for treatment-resistant obsessive-compulsive disorder: a case report with sustained full remission.
    Yeh YW; Chen CH; Kuo SC; Wang SC; Chen CK; Feng HM
    Clin Neuropharmacol; 2009; 32(3):174-6. PubMed ID: 19483491
    [No Abstract]   [Full Text] [Related]  

  • 45. [Psycho- and pharmacotherapy of depressions. So you combine correctly].
    Arnheim K
    MMW Fortschr Med; 2009 May; 151(19):20. PubMed ID: 19827439
    [No Abstract]   [Full Text] [Related]  

  • 46. Duloxetine: a new serotonin/noradrenaline reuptake inhibitor for the treatment of depression.
    Rabasseda X
    Drugs Today (Barc); 2004 Sep; 40(9):773-90. PubMed ID: 15538550
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Duloxetine (cymbalta) for fibromyalgia.
    Med Lett Drugs Ther; 2008 Jul; 50(1291):57-8. PubMed ID: 18654110
    [No Abstract]   [Full Text] [Related]  

  • 48. First preliminary results of a single case report: duloxetine might improve some symptoms of attention-deficit hyperactivity disorder.
    Niederhofer H
    Eur Psychiatry; 2010 May; 25(4):214-5. PubMed ID: 19800768
    [No Abstract]   [Full Text] [Related]  

  • 49. Duloxetine related hypersexuality: a case report.
    Lai CH
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Mar; 34(2):414-5. PubMed ID: 19945494
    [No Abstract]   [Full Text] [Related]  

  • 50. The treatment of urinary incontinence with Duloxetine.
    Basu M; Duckett J
    J Obstet Gynaecol; 2008 Feb; 28(2):166-9. PubMed ID: 18393011
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Duloxetine (Cymbalta): a new SNRI for depression.
    Med Lett Drugs Ther; 2004 Oct; 46(1193):81-2. PubMed ID: 15480298
    [No Abstract]   [Full Text] [Related]  

  • 52. [Evidence-based recommendations for the treatment of fibromyalgia syndrome].
    Harten P; Genth E
    Z Rheumatol; 2010 Jul; 69(5):457-60. PubMed ID: 18836732
    [No Abstract]   [Full Text] [Related]  

  • 53. [Dual acting reuptake inhibitors in the treatment of depression and pain].
    Hajak G
    Dtsch Med Wochenschr; 2006 Dec; 131 Suppl 8():S280-3. PubMed ID: 17139587
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Successful duloxetine use to prevent venlafaxine withdrawal symptoms.
    Hsiao MC; Liu CY
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):576. PubMed ID: 17889418
    [No Abstract]   [Full Text] [Related]  

  • 55. Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder.
    Thase ME; Pritchett YL; Ossanna MJ; Swindle RW; Xu J; Detke MJ
    J Clin Psychopharmacol; 2007 Dec; 27(6):672-6. PubMed ID: 18004135
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Successful phase III study with serotonin-noradrenaline reuptake inhibitor. Soon a drug to control stress incontinence].
    MMW Fortschr Med; 2004 Feb; 146(7):59. PubMed ID: 15347056
    [No Abstract]   [Full Text] [Related]  

  • 57. Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorder.
    Schatzberg AF
    J Clin Psychiatry; 2003; 64 Suppl 13():30-7. PubMed ID: 14552654
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Attributes of response in depressed patients switched to treatment with duloxetine.
    Sagman D; McIntosh D; Lee MS; Li H; Ruschel S; Hussain N; Granger RE; Lee AC; Raskin J
    Int J Clin Pract; 2011 Jan; 65(1):73-81. PubMed ID: 21078010
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.
    Nierenberg AA; Greist JH; Mallinckrodt CH; Prakash A; Sambunaris A; Tollefson GD; Wohlreich MM
    Curr Med Res Opin; 2007 Feb; 23(2):401-16. PubMed ID: 17288694
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Duloxetine: mechanism of action at the lower urinary tract and Onuf's nucleus.
    Jost W; Marsalek P
    Clin Auton Res; 2004 Aug; 14(4):220-7. PubMed ID: 15316838
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.